Wells Fargo Says Outside Interest in Multiple Myeloma Space a Positive for Array Biopharma
Array Biopharma (NASDAQ: ARRY) shares are up over 5 percent in Monday's afternoon session as the earlier Amgen (NASDAQ: AMGN), Onyx (NASDAQ: ONXX) bid and the Celgene (NASDAQ: CELG) MorphoSys partnership signals significant interest in the multiple myeloma space, according to Wells Fargo's Matthew Andrews.
The analyst believes Array's ARRY-520 is an under-appreciated asset in this field.
Andrews maintains an Outperform rating on shares of Array Biopharma.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.